EDITOR: | September 16th, 2013 | 2 Comments

Visionaries at Grafoid make sensational news; Zenyatta weathers the storm admirably

| September 16, 2013 | 2 Comments
image_pdfimage_print
graphene cancer treatment

Addressing cancer treatment: Grafoid’s awe-inspiring joint venture — Calevia Inc. — is working to use graphene as a non-invasive treatment for cancer. Graphene nanoparticles enable drug activation by near infrared light (NIR).

Graphite & Graphene Week-in-Review (for the week ending September 13, 2013): The InvestorIntel Graphite & Graphene members average was down -3.87% for the week. While I’m less than thrilled — to put it mildly — about the news, the overall performance was actually strong if you dig deeper and look at the bigger picture. For starters, there is some very promising news regarding graphene and cancer treatment from Grafoid. As you’ll soon find out, it’s a great story with seemingly unparalleled promise. Also of the brightest stars of the junior graphite market stood up quite well against a coordinated attack by a US-based short seller last week.

Setting the universal standard for graphene: Grafoid Inc. recently announced the formation of Calevia Inc., a joint-venture partnership with ProScan RX Pharma Inc. to develop an entirely new graphene-based nanotechnology platform for the precise targeting and thermal eradication of solid cancer tumors. Focus Graphite Inc. (TSXV: FMS | OTCQX: FCSMF) and Grafoid President and CEO Gary Economo explained that Calevia sets a clear example to the world how graphene technologies serve humanity. As a business, the Grafoid’s patent-pending MesoGraf™ -based therapy leaves Calevia (and Grafoid) well positioned with the potential to actually redefine the treatment for tumorous cancers. In other words, graphene-based cancer treatments aim to overcome the deficiencies, side effects and strong limitations of common cancer therapies such as surgery, radiation and chemotherapy. MesoGraf opens the door for Grafoid to introduce a “universally disruptive technology” to all sectors and it expands Grafoid’s reach into new technology and industrial markets.

Grafoid’s MesoGraf derivative, Mesograf Xide is the latest is the latest development in thermal energy generating nanomaterial science that instamtly transforms near infrared (NIR) light into heat. InvestorIntel’s Dr. Luc Duchesne wrote a fantastic piece last Friday about this, entitled: ‘World’s smallest graphene computer to cure cancer’. Dr. Gordon Chui (the lead scientist at Focus Graphite and co-founder of Grafoid) has collaborated extensively with the National University of Singapore (NUS), where extensive research has been conducted in the area of nanoparticles enabling drug activation by NIR light. It’s fascinating and something to be excited about.

In Focus Graphite news, the company has a new president. Last Friday Focus announced that it had appointment Donald Baxter as President and COO. I am pleased to report that Gary Economo will continue as CEO of Focus Graphite.

ZENPerhaps you already read the story, written by InvestorIntel’s esteemed publisher Tracy Weslosky, entitled: ‘Flagrant foul called on a convicted felon’s short-selling ‘hit’ on Zenyatta’. It sent shock waves throughout the graphite community early last week and, not surprisingly, was a big topic of discussion at the Zenyatta Ventures Ltd. (TSXV: ZEN | OTCQX: ZENYF) AGM in Toronto. There was an impact on Zenyatta’s share prices on Monday, September 9th (the day the story was published) and President and CEO Aubrey Eveleigh wasted no time in responding and issued a new release clarifying commentary related to recent trading activity the following day.

There was a second article — published by the same short seller; an ex-con and alleged organized crime associate who was behind a $50-million-pump-and-dump scam — attacking Zenyatta and libelling Aubrey Eveleigh late last week. The mostr-recent article was factually inaccurate (Aubrey did not have anything to do with the person in question) and said article was pulled offline within hours of publication. It seems overtly apparent that the short-selling publisher has destroyed his own credibility with the “accidental oversight”. Judging from the robust recovery in Zenyatta’s share price on both the American and Canadian exchanges, it appears that the impact of the short-selling story has been neutralized.

A question I’m often asked is ‘what makes Zenyatta different from other graphite?’ The answer is Zenyatta’s deposit contains a different type carbon from all the other graphite plays worldwide, with the exception of Sri Lanka. Zenyatta’s graphite is carbon derived from the earth’s upper mantle, as opposed to all other graphite companies that have carbon derived from organic material. There is apparently a tremendous difference in purity and that is what makes ZEN’s graphite different from all others.

This is how Aubrey Eveleigh explains the difference between his graphite and other graphite companies:

Zenyatta’s graphite consists of carbon derived from the earth’s upper mantle, and NOT carbon derived from organic material (as are most of all other graphite deposits). This is a critical distinction that makes Zenyatta unique and extremely rare.

Since Zenyatta’s graphite is hydrothermal (or volcanic) in origin, the natural graphite crystals have virtually no impurities. It is easy and inexpensive to upgrade using a dilute NaOH/H2O (sodium hydroxide and water) solution to achieve an ultra-high purity of 99.99% graphitic carbon. This means that when graphite crystals are separated from the host rock, the graphite product is very high quality. This can be accomplished without the need to use aggressive acids or high temperature thermal processing to remove impurities. 

Having ultra-high purity graphite means that Zenyatta’s graphite can compete in the synthetic high purity graphite market, which is a multi-billion dollar global market. Organic derived graphite (flake and amorphous) cannot typically achieve high purity (>99.9% graphite) unless expensive hydrometallurgical processes (acid and/or very high temperatures) are applied. Even when high purity is achieved, hydrometallurgical processing can lower the physical characteristics of the product and, therefore, performance.

And, yes, the company is in the midst of proving exactly what it has and it’s purity — in terms of a compliant resource. We can expect to Zenyatta’s 43-101 in late October. With $9 million in the company treasury (at the end of August 2013), Zenyatta is fully funded through to the end of 2014.

Lomiko Metals Inc. (TSXV: LMR | OTCQX: LMRMF) had the strongest showing last week with shares gaining +18.18% on the Canadian exchange. Paul Gill is busy working on advancing Lomiko’s Quartre-Milles graphite property in Quebec.

Here are you numbers for the week: 2013-9-15-Graphite

 

 


InvestorIntel

Editor:

InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.


Copyright © 2016 InvestorIntel Corp. All rights reserved. More & Disclaimer »


Comments

  • Dr. Copper

    Graphite is chemically inert Ty, it has no relevance where it is derived but for its final measured purity state. I hold Zenyatta
    for that reason. C is subject to various heat measuring processes to test thermal conductivity (for impurities) and x-ray diffraction methods (crystallinity) to ascertain graphitization, one way of measuring residual surface material (Yenyattas current method), X-ray fluoroscence analysis is also used. A full spectrum of contaminants is clocked and verified. Zenyatta’s drilling has not shown homogeneity, it is unequal and uneven out-spaced grades at various depth. Economou cannot say that is vein or hydro-thermal type. The opposite is the matter. The host rocks hold the answer to impurities and subsequent purity levels. This is explained by C derived form. The stress level (crystallinity) deteriorates with grinding stages, I assume the graphite will require various grinding stages due to the nature of hard source rock material mixed with lower grades at various depth. The grades has a fairly consistent range providing a good degree of comfort.

    September 20, 2013 - 3:08 PM

  • Creativity proves a timely laxative for capital constipation in the junior markets.

    […] Visionaries at Grafoid make sensational news; Zenyatta weathers the storm admirably […]

    September 23, 2013 - 2:14 PM

Leave a Reply

Your email address will not be published. Required fields are marked *